Transparency related to clinical trial protocols and data has become the expected standard over the past 2 decades, with broad support from patients, the scientific community, and regulatory agencies. Requirements for trial disclosures are codified in US statute and, since 2017, regulation requires timely submission of trial results to ClinicalTrials.gov. However, meaningful clinical trial transparency extends beyond prospective registration and reporting results. The public, for example, must know whether trials were conducted according to international standards for research integrity and must have access to reports investigating departures from good clinical practice guidelines.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials. JAMA. 2020;323(19):1903–1904. doi:10.1001/jama.2020.1631
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: